The collaboration between the 2 drug giants will prove a big boost to Merck's cancer immunotherapy MSB0010718C, and will also improve it's global oncology business.
Merck of Germany said on Monday that the American drug giant Pfizer had agreed to pay $850 million upfront and as much as $2 billion later in a deal to jointly develop one of Merck’s cancer drugs.
The alliance with Pfizer is expected to strengthen Merck’s existing oncology business in several important markets around the world, including the United States, Merck said. The deal also is expected to help spread the cost of developing the drug.
Under the agreement, Merck and Pfizer will jointly develop and commercialize MSB0010718C, a potential treatment for several types of tumor. It is a so-called immuno-oncology drug, which, if successful, would help the body’s own immune system fight cancer.
Complete news report on The New York Times: http://nyti.ms/1Ha1ptq
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen